Introduction. Early malignant tumor detection programs have significantly increased the survival rate of breast cancer patients but the results of drug therapy for this pathology are not always highly effective. Recently discovered iron-dependent cell death, ferroptosis, makes it a promising therapeutic target to reduce the recurrence rates.Objective – to study the induction of ferroptosis in breast cancer cells MCF-7 by quinazoline derivatives synthesized at the Research Institute of Experimental Diagnostics and Therapy of Tumors of the N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia and to evaluate its antitumor activity on transplanted breast carcinoma Ca-755.Materials and methods. Derivatives of 3-hydroxyquinazoline were obtained by chemical synthesis and have a purity of at least 95 %. In this study 2D cultivation of MCF7 cells, phase-contrast and fluorescence microscopy, and a model of experimental growth of breast carcinoma Ca-755 in female hybrids of immunocompetent mice F1 (C57Bl/6 × DBA/2) were used.Results. Five derivatives of 3-hydroxyquinazoline, analogues of erastine, were studied in this work. The ferroptotic cell death was identified by the level of lipid peroxidation at the concentrations of 1/3 and 1/5 IC50. The level of lipid peroxidation induced by compound 3 was comparable with the activity of erastin in MCF7 cells at both 1/3 and 1/5 of IC50, the activity of the other four quinazoline derivatives was 50–70 % of the activity of erastin. In in vivo experiments at a dose of 30 mg/kg the antitumor efficacy of the compound 3 was higher than that of erastin at the same dose.Conclusion. The data obtained suggest that quinazoline derivative 3 might be considered as a promissisng antitumor agent to treat breast cancer.
Introduction. The main cause of clinical progression of tumor under the conditions of treatment is the resistance. Reactivate apoptosis in resistant to chemotherapy cells is impossible, the tumor grows into an irreversible growth phase. Recently published data on the ability of ferroptosis inducers to induce the death of resistant cells opens up new possibilities for improving the effectiveness of antitumor therapy.The purpose of the study – assessment of the mechanism of ferroptosis induction of the synthesized analogue of erastin OVN‑002 on Mel Z melanoma cells and investigation of its antitumor activity on transplanatated B‑16 melanoma of mice.Materials and methods. In this study 2D cultivation of metastatic Mel Z melanoma cells, phase‑contrast and fluorescence microscopy, and a model of experimental growth of B‑16 melanoma in female hybrids of immu‑ nocompetent mice F1 (C57Bl/6 × DBA / 2) were used. The antitumor effect was evaluated by measurement of tumor growth inhibition (TGI, %) and increase of life span of the treated animals as compared to the control ones.Results. The cytotoxic activity of OVN‑002 was equal to the activity of erastin on metastatic melanoma cells Mel Z: 744 ± 20 and 719 ± 20 a. u., respectively. OVN‑002 at a dose 50 mg / kg reduced the growth of experimental melanoma B‑16 about 81 % (TGI 81–57 %, p 0.05). The effect was stable up to 7th day, while erastin showed only a direct antitumor effect (TGI 65 %, p 0.05).Conclusion. The data obtained suggest that OVN‑002 might be considered as a novel antitumor agent.
The study investigated antitumor activity of 10 new compounds in the series of N-glycosides of indolo[2,3-a] carbazoles. The results identified strong antitumor activity of compounds LCS-1208, LCS -1054, LCS -999 and LCS-1006 against lymphocytic leukemia P-388 (ILS=85 - 119%). Glycosides LCS-1208, LCS-999 and LCS-1006 exhibited high antitumor activity immediately after treatment for Lewis epidermoid lung carcinoma LLC (TGI =90%). In addition, the antitumor effect after LCS-999 and LCS-1006 treatment kept on for 10 days, and LCS-1208 - for 15 days. Glycoside LCS-1208 had a therapeutic efficiency on melanoma B-16 for 7 days (TGI=91 - 58%). Thus, the study of relation «structure-activity» in a series of derivatives of N-glycosides of indolo[2,3-a]carbazoles allowed to select highly effective compound LCS-1208 for preclinical studies.
Introduction . The report considers the prospect of rational approach to the new anticancer agents creation based on indolocarbazole derivatives.Objective . To conduct a comparative study of 12 domestic N-glycosides, indolo[2,3-a]pirrolo[2,3-a]carbazole derivatives in the course of “structure – activity” bond analysis.Materials and methods . The investigation of influence of 12 carbohydrate – containing indolocarbazoles, synthesized in N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of Russia, performed on models of solid transplantable mouse tumors: lung Lewis epidermoid carcinoma and B16 melanoma. The antitumor effect was assessed by Lewis epidermoid carcinoma and B16 melanoma tumor growth inhibition (TGI %) criterion.Results . A variety of indolocarbazoles modifications allowed revealing the dependence of their antitumor properties on the structure of both, the aglycone and the glycoside residue. Imino-nitrogen interchange of atoms in upper heterocycle influences on indocarbazole derivatives antitumor activity change. During a comparative study of 12 N-glycosides indolocarbazole derivatives on lung Lewis epidermoid carcinoma and B16 melanoma models, 8 derivatives showed antitumor activity.Conclusion . The formulated concepts on the modification features in indolocarbazole derivatives structure can be used for more active compounds creation with greater action selectivity.
The paper discusses the possible mechanisms of antitumor action of indolocarbazole derivatives. Here we present a data that show interaction drugs based on indolocarbazole derivatives with several intracellular targets and consequently activation different pathways of cell death. Also we present results of our studies on the mechanisms of antitumor action of compounds LCS-1006 and LCS-1208 synthesized in the N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia.
15 January 2020 in Bulletin of Experimental Biology and Medicine